TQS-168 Found to Reduce Inflammation, Extend Survival in Mice

TQS-168 Found to Reduce Inflammation, Extend Survival in Mice

311849

TQS-168 Found to Reduce Inflammation, Extend Survival in Mice

TQS-168, an investigational therapy being developed by Tranquis Therapeutics, reduced inflammation in mouse and human models of amyotrophic lateral sclerosis (ALS), and prolonged survival in the mice, according to a preclinical study. Based on these findings, Tranquis is moving the therapy into Phase 1 clinical studies. “We believe TQS-168 represents a new class of treatment for ALS patients and these data paint a compelling picture which shows, in this preclinical model, a potential advance over…

You must be logged in to read/download the full post.